Published, Version of Record (VoR)CC BY V4.0, Open
Abstract
Biotechnology & Applied Microbiology Genetics & Heredity Life Sciences & Biomedicine Medicine, Research & Experimental Pathology Research & Experimental Medicine Science & Technology
Changes in N-linked glycosylation are known to occur during the development of various diseases. For example, increased branching of oligosaccharides has been associated with cancer metastasis and has been correlated to tumor progression in human cancers of the breast, colon and melanomas. Increases in core fucosylation have also been associated with the development of hepatocellular carcinoma (HCC). Recently, changes in both the total serum glycome and the glycosylation of specific IgG molecules have been observed in people with liver fibrosis and cirrhosis. The mechanisms by which changes in glycosylation are observed and their use as biomarkers of disease will be discussed.
Fucosylated glycoproteins as markers of liver disease
Creators
Anand Mehta - Drexel University
Timothy M. Block - Drexel University
Publication Details
Disease markers, v 25(4-5), pp 259-265
Publisher
Hindawi Publishing Group
Number of pages
7
Grant note
Commonwealth of Pennsylvania
Hepatitis B Foundation
R01CA120206 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
UO1 CA084951-06; R01 CA120206-01 / National Cancer Institute (NCI); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Resource Type
Journal article
Language
English
Academic Unit
Microbiology and Immunology
Web of Science ID
WOS:000263028900007
Scopus ID
2-s2.0-58149400525
Other Identifier
991019167527204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: